Lung cancer survival in patients with autoimmune disease
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy.
However, the association between autoimmune disease and lung cancer survival is largely unknown.
The objective of retrospective cohort study between 2003 and 2019 at a single academic medical center ( Northwestern University ) was to determine the association between autoimmune disease and lung cancer survival.
Researchers have identified 349 patients with lung cancer and several autoimmune diseases.
Types of lung cancers included small cell, adenocarcinoma, squamous cell carcinoma, non-small cell not otherwise specified, and large cell carcinoma.
Autoimmune diseases included rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, myositis, and Sjögren syndrome.
Inclusion criteria were biopsy-confirmed lung cancer, autoimmune diagnosis confirmed by a rheumatologist, and death or an encounter listed in the electronic medical record within 2 years of study end.
A control group of patients with biopsy-proven lung cancer but without autoimmune disease was identified.
Data analysis was conducted from March to July 2020.
The primary endpoints were overall survival ( OS ) and progression-free survival ( PFS ) in patients with autoimmune disease.
The hypothesis was that patients with autoimmune disease would have worse progression-free survival and overall survival compared with patients in the control group.
Of the original 349 patients, 177 met inclusion criteria. Mean age at lung cancer diagnosis was 67.0 years and 136 ( 76.8% ) were women.
Most common autoimmune diseases were rheumatoid arthritis ( 97 [ 54.8% ] ), systemic sclerosis ( 43 [ 24.3% ] ), and systemic lupus erythematous ( 15 [ 8.5% ] ).
Most common lung cancers were adenocarcinoma ( 99 [ 55.9% ] ), squamous cell carcinoma ( 29 [ 16.4% ] ), and small cell lung cancer ( 17 [ 9.6% ] ).
A total of 219 patients ( mean age at diagnosis, 65.9 years; 173 [ 79.0% ] ) were identified as having lung cancer without autoimmune disease and included in the control cohort.
Compared with patients in the control group, patients with autoimmune disease experienced no difference in overall survival ( log-rank P = 0.69 ).
A total of 126 patients ( 69.5% ) with autoimmune disease received standard of care vs 213 patients ( 97.3% ) in the control group ( P less than 0.001 ).
No individual autoimmune disease was associated with worse prognosis, even among patients with underlying interstitial lung disease.
In conclusion, compared with institutional controls, patients with autoimmune disease experienced no difference in survival despite the fact that fewer patients in this group received standard-of-care treatment.
No individual autoimmune disease was associated with worse prognosis.
Future multicenter prospective trials are needed to further evaluate autoimmune disease and lung cancer survival. ( Xagena )
Jacob S et al. JAMA Netw Open 2020. PMID: 33315114
FDA has approved Ponvory, an oral treatment for adults with relapsing multiple sclerosis proven superior to Aubagio in reducing annual relapses and brain lesions
The U.S. Food and Drug Administration ( FDA ) has approved Ponvory ( Ponesimod ), a once-daily oral selective sphingosine-1-phosphate...
A small number of patients receiving Dimethyl fumarate ( Tecfidera ) for the treatment of multiple sclerosis have developed progressive...
Ponvory for the treatment of adults with relapsing forms of multiple sclerosis with active disease - Approved in European Union
The European Commission ( EC ) has approved Ponvory ( Ponesimod ) for the treatment of adult patients with relapsing...
Kesimpta, self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis, FDA approved
The FDA ( US Food and Drug Administration ) has approved Kesimpta ( Ofatumumab, formerly OMB157 ) as an injection...
Living near major roads or highways is linked to higher incidence of dementia, Parkinson's disease, Alzheimer's disease and multiple sclerosis,...
Mayzent for adult patients with secondary progressive multiple sclerosis with active disease, approved in European Union
The European Commission ( EC ) has approved Mayzent ( Siponimod ) for the treatment of adult patients with secondary...
Effect of baseline age on efficacy and safety of Siponimod in patients with active secondary progressive multiple sclerosis
Siponimod ( Mayzent ) is a selective sphingosine 1-phosphate receptor ( S1P1 and S1P5 ) modulator, approved in the USA...
Relapsing multiple sclerosis: Ofatumumab has demonstrated superiority versus Teriflunomide in ASCLEPIOS I and II
Positive results for Ofatumumab ( OMB157 ) from the phase III ASCLEPIOS I and II studies were announced. In both...
Satralizumab, an anti-IL-6 receptor monoclonal antibody, reduces relapse risk for neuromyelitis optica spectrum disorder
Full pivotal phase III SAkuraStar study results for Satralizumab as a monotherapy for neuromyelitis optica spectrum disorder ( NMOSD ),...